SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited
Filed with ASX · · 3 pages · English
• Final patient recruited into Syntara’s randomised, double-blind, placebo-controlled Phase 2 study of first-in-class neuro-targeted antiinflammatory therapy, SNT-4728, to treat isolated REM Sleep Behaviour Disorder (iRBD). • iRBD affects around 2% of individuals over 50 years of age, and up to 90% of these patients progress to a neurodegenerative disease, highlighting a substantial unmet medical
Earlier from Syntara
- Skin scarring program to progress on positive Phase1a result
- Quarterly Shareholder Report and Appendix 4C
- Positive top-line Phase 2a data confirms competitive profile
- Preliminary Final Report
- Guidance from FDA on amsulostat clinical progression
Later from Syntara
- Amsulostat and Garvan in MRFF funded pancreatic trial
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Year Report and Appendix 4D
- Positive FDA feedback for Amsulostat P2b trial
- Continuation of trading halt
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara